Rheumatoid Arthritis-Associated Interstitial Lung Disease

WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.

WASHINGTON — Healio spoke with Jeffrey A. Sparks, MD, MMSc, about baseline results from the SAIL-RA study, which assesses which patients with rheumatoid arthritis may be at risk for developing interstitial lung disease.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, highlights an observational study investigating the impact of disease-modifying antirheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.

SAN DIEGO — TNF inhibitors demonstrate comparable risks for hospitalization and death vs. non-TNF agents in patients with rheumatoid arthritis-associated interstitial lung disease, according to data presented at ACR Convergence 2023.

SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, highlighted studies from members of his group at Brigham and Women’s Hospital that were presented at ACR Convergence 2023.

SAN DIEGO — In this video, Jeffrey A. Sparks, MD, MMSc, spoke with Healio about the safety of TNF inhibitors compared with alternative targeted therapies for patients with rheumatoid arthritis-associated interstitial lung disease.

SAN DIEGO — Kathryn Dao, MD, discusses a study presented at ACR Convergence 2023 that compared the initiation of TNF inhibitors with non-TNF inhibitor biologics or JAK inhibitors among patients with rheumatoid arthritis-associated interstitial lung disease.

PHILADELPHIA — Significant and distinct shifts in critical “cellular players” were seen among patients with rheumatoid arthritis-associated interstitial lung disease, according to an ongoing study presented at ACR Convergence 2022.

The most frequent cause of death in patients with rheumatoid arthritis-associated interstitial lung disease and also those with idiopathic pulmonary fibrosis is acute exacerbation, researchers reported.

In patients with rheumatoid arthritis-associated interstitial lung disease, more severe RA disease activity and impaired functional status were associated with increased mortality, according to data presented at ACR Convergence 2021.